| 晚期非小细胞肺癌初始治疗后再次应用EGFR-TKI的疗效观察 |
| |
| 引用本文： | 安形同,黄真,王玉艳,王志杰,白桦,王洁. 晚期非小细胞肺癌初始治疗后再次应用EGFR-TKI的疗效观察[J]. 中国肺癌杂志, 2011, 14(3): 261-265. DOI: 10.3779/j.issn.1009-3419.2011.03.22 |
| |
| 作者姓名： | 安形同 黄真 王玉艳 王志杰 白桦 王洁 |
| |
| 作者单位： | 1. 北京大学肿瘤医院胸部肿瘤内科,北京,100142
2. 北京积水潭医院骨肿瘤科,北京,100036 |
| |
| 摘 要： | 背景与目的表皮生长因子受体酪氨酸激酶抑制剂(epidermalgrowthfactorreceptortyrosinekinaseinhibi-tor,EGFR-TKI)是化疗失败的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的标准二三线治疗方案,亦是EGFR突变患者一线治疗的最佳选择,但对初始治疗后进展的患者,在治疗过程中能否再次使用TKI是目前的关注热点。本研究旨在探讨晚期NSCLC初始治疗后再次应用EGFR-TKI的疗效。方法本研究回顾性分析了71例晚期或术后复发的NSCLC初始EGFR-TKI治疗后,再次应用TKI的疗效。结果 71例再次应用TKI的患者中,部分缓解(par-tial response,PR)为7%,稳定(stable disease,SD)为36.6%,(progressive disease,PD)为56.3%,疾病控制率(diseasecontral rate,DCR)为43.7%,无进展生存期(progression free survival,PFS)>3个月者26例(36.6%)。EGFR21外显子突变、初始TKI缓解期6个月、两次TKI的间隔期3个月与更长的PFS相关,单因素COX回归分析,P值分别为0.034、0.013、0.046。结论 TKI治疗失败的NSCLC患者再次应用TKI,部分患者仍可获得疾病控制。EGFR21外显子突变、初始TKI缓解期6个月、两次TKI间隔期3个月的患者更可能从再次应用TKI中获益。
|
| 关 键 词： | 肺肿瘤 表皮生长因子受体 吉非替尼 厄洛替尼 |
Retreatment with Epidermal Growth Factor Receptor Inhibitor After Initial Failure in Advanced Non-small Cell Lung Cancer |
| |
| Tongtong AN,Zhen HUANG,Yuyan WANG,Zhijie WANG,Hua BAI,Jie WANG. Retreatment with Epidermal Growth Factor Receptor Inhibitor After Initial Failure in Advanced Non-small Cell Lung Cancer[J]. Chinese journal of lung cancer, 2011, 14(3): 261-265. DOI: 10.3779/j.issn.1009-3419.2011.03.22 |
| |
| Authors: | Tongtong AN Zhen HUANG Yuyan WANG Zhijie WANG Hua BAI Jie WANG |
| |
| Affiliation: | Tongtong AN 1,Zhen HUANG 2,Yuyan WANG 1,Zhijie WANG 1,Hua BAI 1,Jie WANG 1 1 Department of oracic Oncology,Beijing Cancer Hospital,Beijing University Oncology College,Beijing 100142,China,2 Department of Osteoma,Beijing Ji Shui Tan Hospital,Beijing 100036 |
| |
| Abstract: | Background and objective The epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) shows favorable antitumor activity against chemorefractory non-small cell lung cancer(NSCLC) .However,patients with advanced NSCLC have limited treatment options available if they are refractory to EGFR-TKI.To study the in uence of the retreatment EGFR-TKI a er failure of rst-line TKI,we carried out this retrospective study.Methods Total 71 patients were analyzed who experienced treatment failure from their ini... |
| |
| Keywords: | Lung neoplasms Fctor receptor tyrosine kinase inhibitor Gefitinib Erlotinib |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
